BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 34227399)

  • 21. Desmoid Fibromatosis With TP53 Mutation and Striking Nuclear Pleomorphism.
    Foster CR; Strauss M; Hornick JL; Habeeb O
    Int J Surg Pathol; 2023 Dec; 31(8):1565-1571. PubMed ID: 36908221
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Desmoid tumors of the head and neck: a therapeutic challenge.
    de Bree E; Zoras O; Hunt JL; Takes RP; Suárez C; Mendenhall WM; Hinni ML; Rodrigo JP; Shaha AR; Rinaldo A; Ferlito A; de Bree R
    Head Neck; 2014 Oct; 36(10):1517-26. PubMed ID: 24421052
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Desmoid-Type Fibromatosis: Evolving Treatment Standards.
    Fiore M; MacNeill A; Gronchi A; Colombo C
    Surg Oncol Clin N Am; 2016 Oct; 25(4):803-26. PubMed ID: 27591500
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Next-generation sequencing is highly sensitive for the detection of beta-catenin mutations in desmoid-type fibromatoses.
    Aitken SJ; Presneau N; Kalimuthu S; Dileo P; Berisha F; Tirabosco R; Amary MF; Flanagan AM
    Virchows Arch; 2015 Aug; 467(2):203-10. PubMed ID: 25838078
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fibromatosis of the breast: a 10-year multi-institutional experience and review of the literature.
    Boland MR; Nugent T; Nolan J; O'Mahony J; O'Keeffe S; Gillham CC; Maguire A; Geraghty J; McCartan D; Evoy D; Prichard RS; McDermott EW; Alazawi D; Boyle TJ; Connolly EM
    Breast Cancer; 2021 Jan; 28(1):168-174. PubMed ID: 32780320
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG).
    Kasper B; Baumgarten C; Garcia J; Bonvalot S; Haas R; Haller F; Hohenberger P; Penel N; Messiou C; van der Graaf WT; Gronchi A;
    Ann Oncol; 2017 Oct; 28(10):2399-2408. PubMed ID: 28961825
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Desmoid tumors: clinical features and treatment options for advanced disease.
    Kasper B; Ströbel P; Hohenberger P
    Oncologist; 2011; 16(5):682-93. PubMed ID: 21478276
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Desmoid tumor: from surgical extirpation to molecular dissection.
    Lazar AJ; Hajibashi S; Lev D
    Curr Opin Oncol; 2009 Jul; 21(4):352-9. PubMed ID: 19436199
    [TBL] [Abstract][Full Text] [Related]  

  • 29. β-catenin (CTNNB1) mutations and clinicopathological features of mesenteric desmoid-type fibromatosis.
    Huss S; Nehles J; Binot E; Wardelmann E; Mittler J; Kleine MA; Künstlinger H; Hartmann W; Hohenberger P; Merkelbach-Bruse S; Buettner R; Schildhaus HU
    Histopathology; 2013 Jan; 62(2):294-304. PubMed ID: 23020601
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Prospective Observational Study of Active Surveillance in Primary Desmoid Fibromatosis.
    Colombo C; Fiore M; Grignani G; Tolomeo F; Merlini A; Palassini E; Collini P; Stacchiotti S; Casali PG; Perrone F; Mariani L; Gronchi A
    Clin Cancer Res; 2022 Sep; 28(18):4027-4032. PubMed ID: 35247923
    [TBL] [Abstract][Full Text] [Related]  

  • 31. β-Catenin mutation status and outcomes in sporadic desmoid tumors.
    Mullen JT; DeLaney TF; Rosenberg AE; Le L; Iafrate AJ; Kobayashi W; Szymonifka J; Yeap BY; Chen YL; Harmon DC; Choy E; Yoon SS; Raskin KA; Hornicek FJ; Nielsen GP
    Oncologist; 2013; 18(9):1043-9. PubMed ID: 23960186
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors.
    Lazar AJ; Tuvin D; Hajibashi S; Habeeb S; Bolshakov S; Mayordomo-Aranda E; Warneke CL; Lopez-Terrada D; Pollock RE; Lev D
    Am J Pathol; 2008 Nov; 173(5):1518-27. PubMed ID: 18832571
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characteristics of cultured desmoid cells with different CTNNB1 mutation status.
    Hamada S; Urakawa H; Kozawa E; Arai E; Ikuta K; Sakai T; Ishiguro N; Nishida Y
    Cancer Med; 2016 Feb; 5(2):352-60. PubMed ID: 26686699
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Nationwide Prospective Clinical Trial on Active Surveillance in Patients With Non-intraabdominal Desmoid-type Fibromatosis: The GRAFITI Trial.
    Schut AW; Timbergen MJM; van Broekhoven DLM; van Dalen T; van Houdt WJ; Bonenkamp JJ; Sleijfer S; Grunhagen DJ; Verhoef C
    Ann Surg; 2023 Apr; 277(4):689-696. PubMed ID: 35166264
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term Outcomes of Oral Vinorelbine in Advanced, Progressive Desmoid Fibromatosis and Influence of
    Mir O; Honoré C; Chamseddine AN; Dômont J; Dumont SN; Cavalcanti A; Faron M; Rimareix F; Haddag-Miliani L; Le Péchoux C; Levy A; Court C; Briand S; Fadel E; Mercier O; Bayle A; Brunet A; Ngo C; Rouleau E; Adam J; Le Cesne A
    Clin Cancer Res; 2020 Dec; 26(23):6277-6283. PubMed ID: 32873570
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Event-free survival in Desmoid-Type fibromatosis (DTF): A pre-post comparison of upfront surgery versus wait-and-see approach.
    Ruspi L; Cananzi FCM; Sicoli F; Samà L; Renne SL; Marrari A; Gennaro N; Colombo P; Cozzaglio L; Politi LS; Bertuzzi A; Quagliuolo V
    Eur J Surg Oncol; 2021 May; 47(5):1196-1200. PubMed ID: 32847695
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effective treatment of aggressive fibromatosis with celecoxib guided by genetic testing.
    Yang S; Wang X; Jiang H; Wang Y; Li Z; Lu H
    Cancer Biol Ther; 2017 Oct; 18(10):757-760. PubMed ID: 28881160
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Extra-abdominal desmoid fibromatosis--a sarcoma unit review of practice, long term recurrence rates and survival.
    Eastley N; Aujla R; Silk R; Richards CJ; McCulloch TA; Esler CP; Ashford RU
    Eur J Surg Oncol; 2014 Sep; 40(9):1125-30. PubMed ID: 24612653
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Wnt targets genes are not differentially expressed in desmoid tumors bearing different activating β-catenin mutations.
    Timbergen MJM; Janssen ML; Verhoef C; Grünhagen DJ; Chibon F; Smid M; Sleijfer S; Wiemer EAC
    Eur J Surg Oncol; 2019 Apr; 45(4):691-698. PubMed ID: 30528042
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Evolving Management of Desmoid Fibromatosis.
    Prendergast K; Kryeziu S; Crago AM
    Surg Clin North Am; 2022 Aug; 102(4):667-677. PubMed ID: 35952695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.